Key facts
- Niche Biopharmaceuticals’s last known valuation is $30.0M.
- It has raised $330K.
- Niche Biopharmaceuticals has filed 3 Form Ds with the SEC since 2021, most recently May 2025 ($100K sold to 2 investors).
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Niche Biopharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Niche Biopharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Niche Biopharmaceuticals
Developer of coupled anti-infective immunomodulatory therapeutics designed for antimicrobial and antiviral treatment. The company's lead compound exhibits activity in the microgram-per-milliliter range and, combined with anti-inflammatory properties, including resistance-refractory efficacy over extended culture, as well as potent effects on envelope viruses, enabling infectious disease and dermatology markets to access chemical entities with multi-functional therapeutic potential.
- Sector
- Healthcare
- HQ
- Shorewood, MN, United States
- Founded
- 2020
- Website
- nichebiopharma.com/
- Ownership
- Privately Held (backing)
Niche Biopharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Niche Biopharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Niche Biopharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.